SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R ...

Gilead Sciences, Inc. (NASDAQ:GILD) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 9:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Joseph Catanzaro - Piper Sandler Joseph Catanzaro Perfect. Great. Well, appreciate everybody joining us here on the second day of Piper Sandler's Annual Healthcare Conference. I am Joe Catanzaro, one of Piper's biotech analysts. My real pleasure to kick off this session here with Gilead. Joining us is the ...

Gilead Sciences, Inc. (NASDAQ:GILD) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Let's get ahead and get started. Thank you all for being here. Pleasure to have Gilead management here. There's a lot of topics to go through, including some of the FDA updates today, Andy, and I realized it's very early into the update. But maybe let me turn it over t ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies London Healthcare Conference November 15, 2023 4:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Michael Yee - Biotech Analyst, Jeffries Michael Yee Okay, good morning. Thank you everyone for joining us on a morning session here on day two of the Jeffries Global London Healthcare Conference. I'm Mike Yee, one of the biotech analysts at Jeffries, and I'm really pleased to have with us up here on the stage the ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Geoff Meacham - Bank of America Michael Yee - Jefferies Daina Graybosch - Leerink Partners ...

Q323 Financial Results November 7, 2023 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its anticipated full ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jur ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_4480560867daa7897cdca7c4f81be1aa.html ...

Summary of Gilead Sciences, Inc. Conference Call Company Overview - **Company**: Gilead Sciences, Inc. (NASDAQ: GILD) - **Date**: September 6, 2023 - **Participants**: Andrew Dickinson (CFO), Mohit Bansal (Wells Fargo Analyst) Key Points on HIV Business - **Market Growth**: The HIV treatment market is growing at a rate of 2% to 3% annually in the US, with the prevention market experiencing a significant growth of approximately 20% over the last couple of years [4][5] - **Product Performance**: Descovy holds over 40% of the HIV prevention market in the US, indicating strong commercial performance despite competition from generics [7] - **Long-Acting Therapies**: Gilead is developing lenacapavir, a novel HIV capsid inhibitor, which is expected to change the prevention market dynamics by ensuring better adherence and compliance [7][9] - **Future Outlook**: The HIV treatment franchise, including Biktarvy and Descovy, is expected to continue growing through the end of the decade and beyond, despite concerns about generics entering the market [11] Key Points on Oncology Business - **Market Position**: Gilead's oncology business is currently valued at $3 billion and is expected to grow rapidly, with significant advancements in cell therapy and antibody-drug conjugates [20] - **TRODELVY Performance**: The combination of TRODELVY with PD-1 therapy showed a response rate of approximately 70% in high PD-L1 expressers, significantly higher than the standard of care [20][21] - **Safety Profile**: TRODELVY has a well-defined safety profile, which is crucial for its acceptance in first-line therapies [23] - **TIGIT Development**: Gilead's TIGIT antibody is expected to provide additive benefits when combined with PD-1 therapies, with ongoing studies to validate its efficacy [26] Financial and Strategic Insights - **R&D and SG&A Spending**: Gilead has increased its R&D and SG&A spending to support its growth ambitions, aligning its spending levels with industry benchmarks [30] - **Operating Margins**: Despite increased spending, Gilead maintains one of the strongest operating margins in the industry, with expectations for continued growth in EPS [30] - **Business Development Strategy**: Gilead is focusing on earlier-stage deals to fill its pipeline, indicating a strategic shift towards maintaining a robust portfolio without the need for large acquisitions [32][33] Additional Insights - **Market Dynamics**: The shift towards long-acting therapies in both treatment and prevention is expected to significantly expand the market, particularly in HIV prevention [15][16] - **Compliance Issues**: Compliance remains a challenge in both treatment and prevention settings, highlighting the importance of developing therapies that ensure adherence [18] - **Future Data Releases**: Upcoming data releases, particularly for EVOKE-02 and other clinical studies, are anticipated to provide further insights into Gilead's product efficacy and market positioning [19][20] This summary encapsulates the key insights from the conference call, focusing on Gilead's strategic direction, market performance, and future growth potential in both the HIV and oncology sectors.

Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Geoff Meacham - Bank of America Chris Schott - JPMorgan Tyler Van Buren - TD Cowen Terrence F ...